Mr. Hasnain is the Co-Founder, Chairman and Chief Executive Officer of Gossamer Bio. Prior to co-founding Gossamer Bio, Mr. Hasnain served as President, CEO and as a Director of Receptos, Inc. from November 2010 to August 2015. Receptos was a public company formed in 2009 focused on developing treatments in immunology and metabolic disorders and was purchased by Celgene Corporation in August 2015. Previously, Mr. Hasnain was the President and Chief Executive Officer and a director of Facet Biotech Corporation, a biology-driven antibody company with a focus in multiple sclerosis and oncology. He held that position from December 2008 until the company’s acquisition by Abbott Laboratories in April 2010. Previously, Mr. Hasnain was President, Chief Executive Officer and a director of PDL BioPharma, Inc. from October 2008 until Facet Biotech was spun off from PDL BioPharma in December 2008. From October 2004 to September 2008, Mr. Hasnain served at Biogen Idec Inc., a biotechnology company specializing in neurological disorders, autoimmune disorders and cancer, most recently as Executive Vice President in charge of the oncology/rheumatology strategic business unit. Prior to Biogen Idec, Mr. Hasnain held roles with Bristol Myers Squibb, where he was President of the Oncology Therapeutics Network, and for 14 years at GlaxoSmithKline and its predecessor organizations. He has been Chairman of the Board of Sente, Inc. since 2008, Chairman of the Board of Mirati Therapeutics, Inc. since February 2019 and a member of the Board of Overseers of Scripps Research Institute since 2018. He previously served as Chairman of the Board of Ambit Biosciences Corporation and Tocagen Inc. and served as a member of the Board of Directors of Tercica, Inc., Aragon Pharmaceuticals, Somaxon Pharmaceuticals, Inc. and Vital Therapies, Inc. Mr. Hasnain received a B.H.K. and B.Ed. from the University of Windsor Ontario in Canada.

Richard Aranda, M.D. has served as our Chief Medical Officer since June 2021, previously having served as our Senior Vice President and Head of Clinical Development since joining Gossamer in February 2018. Prior to joining Gossamer Bio, Dr. Aranda was Vice President of Clinical Development at Receptos, Inc. (Celgene Corporation), from 2015 to 2018, where he contributed to the late-stage development programs for ozanimod (Zeposia) in multiple sclerosis and inflammatory bowel disease (IBD) and RPC4046 in eosinophilic esophagitis. Before joining Receptos, from 2011 to 2015, Dr. Aranda was Vice President of Medical-Science and Inflammation at Novo-Nordisk, Inc., where he played a key role in advancing several biologic product candidates through Phase 1 to proof-of-concept studies in rheumatoid arthritis (RA), systemic lupus erythematosus and IBD. Dr. Aranda began his industry career at Bristol Myers Squibb in 2001, where he held roles of increasing scope and responsibility, including serving as the Global Medical Lead for abatacept (Orencia), as well as Early Development Team Lead for early-stage immunology product candidates. As the Global Medical Lead, Dr. Aranda contributed to the development and approval of Orencia for the treatment of RA and juvenile arthritis and the exploration of Orencia in other immune-mediated disorders. Before joining the pharmaceutical industry, Dr. Aranda was on the faculty of the Division of Digestive Diseases and West Los Angeles Veterans Affairs, University of California, Los Angeles (UCLA) School of Medicine where he was involved in patient care and laboratory based immunological research. Dr. Aranda received his medical training at Harbor-UCLA and clinical fellowship and immunology research training through the UCLA integrated Gastroenterology Training Program. He received his M.D. from Stanford Medical School and his undergraduate degree from the University of California, Santa Cruz.

Mr. Boerneke has served as General Counsel and Secretary of Gossamer Bio since 2021 and as our Associate General Counsel since April 2018. Previously, from 2015 to 2018, Mr. Boerneke served as corporate counsel at Amgen Inc. Prior to joining Amgen, he was an associate at Latham & Watkins LLP. Mr. Boerneke received his J.D. from the University of California Los Angeles School of Law and a B.S. in chemistry from Point Loma Nazarene University.

Mr. Cravets joined Gossamer Bio in November 2018 and has served as our Senior Vice President of Biometrics since March 2021. Prior to joining Gossamer Bio, Mr. Cravets was Vice President of Biometrics at Heron Therapeutics Inc. from 2016 to 2018, where he played a key role in the late-stage development programs for Zynrelef for the treatment post-surgical pain and Cinvanti for the prevention of chemotherapy induced nausea and vomiting.  Before joining Heron, Mr. Cravets was Executive Director of Biometrics at Receptos Inc. from 2014 to 2016, where he built the biostatistics and data management functions while contributing to mid- and late-stage development programs for ozanimod (Zeposia) in multiple sclerosis (MS) and inflammatory bowel diseases (IBD).  Before joining Receptos, Mr. Cravets was the head of biostatistics at Ardea Biosciences from 2011 to 2014, building the biostatistics function while also making significant contributions to the designs and analyses of late-stage studies of lesinurad (Zurampic) for the treatment of gout. From 2003 to 2011 Mr. Cravets served in roles of increasing responsibility in the biostatistics group at Biogen Idec Inc., contributing to the successful regulatory approvals of rituximab (Rituxan) in both rheumatoid arthritis (RA) and chronic lymphocytic leukemia (CLL). From 1996 to 2003, Mr. Cravets was in the biostatistics group at Amgen, Inc., working on multiple products across various neurology, rheumatology, cardiovascular, and bone disease indications.  Mr. Cravets began his career in the pharmaceutical products division of Abbott Laboratories in 1994 after completing his master’s degree in statistics at the University of Michigan and his bachelor’s degree in mathematics at UCLA.

Bryan Giraudo has served as the Chief Financial Officer of Gossamer Bio since May 2018 and Chief Operating Officer since September 2021. Bryan has completed nearly $1.0 billion in financings for Gossamer since inception from Series B, thru IPO and additional debt and equity financings. Prior to joining Gossamer, Mr. Giraudo was a Senior Managing Director at Leerink Partners from 2009 to April 2018, where he was responsible for their western North America and Asia Pacific biotechnology and medical technology banking practice. Before joining Leerink, Mr. Giraudo was a Managing Director in Merrill Lynch and Co.’s Global Healthcare Investment Banking Group. He joined Merrill Lynch in 1997. As a banker, he has completed over 200 corporate finance, corporate partnership and strategic advisory transactions. He has been a member of the board of directors of Protagonist Therapeutics, Inc. since May 2018 and Onxeo SA since November 2021. Mr. Giraudo received his B.A. from Georgetown University.

Dr. Nolan joined Gossamer Bio in October 2019 as Managing Director and President, Gossamer Bio Ireland, where she is responsible for the leadership of the company’s ex-US operations based in Dublin, Ireland. Prior to joining Gossamer, she served as Chief Business Officer for several public and private biotech companies in the US & Canada including Rexahn Pharmaceuticals, Relmada Therapeutics, and Topigen. She has also held senior positions in business development and strategic marketing with Skyepharma and with West Pharmaceutical Services. She spent her early career with Elan Corporation and with Zeneca Pharmaceuticals in Europe where she served in broad ranging roles in clinical research, regulatory and various commercial roles. Dr. Nolan holds a M.Sc. in pharmacy and a Ph.D. in clinical pharmacology from Trinity College, Dublin. 

Caryn Peterson has served as our Executive Vice President, Regulatory Affairs since April 2021 and as our Senior Vice President, Regulatory & Quality since April 2018. Previously, from 2004 to 2018, Ms. Peterson served as Managing Partner of Development & Strategic Consulting (“DSC”) Associates, LLC, focusing on the development, integration, and implementation of global clinical and regulatory strategy across a broad range of therapeutic areas. From 2008 to 2018, Ms. Peterson also served as Vice President, Regulatory Affairs at Syndax Pharmaceuticals, Inc. From 1997 to 2004, Ms. Peterson served as Vice President of Regulatory Affairs at FeRx Incorporated, and from 1989 to 1997, Ms. Peterson held managerial positions in both Pharmaceutical Development and Regulatory Affairs at Amylin Pharmaceuticals. Prior to joining Amylin, Ms. Peterson was a staff scientist at Hybritech Incorporated from 1981 to 1989. Ms. Peterson has coauthored several research publications and is a co-inventor on multiple patent applications.

Mr. Smith has over 30 years of experience in pharmaceuticals, with a strong focus on PAH and rare disease. Prior to joining Gossamer, Mr. Smith was the National Sales Lead in charge of preparing for the potential launch of sotatercept for the treatment of PAH in the US at Merck & Co. Prior to this, Mr. Smith was the President of LTM Pharma Consulting, where he helped build strategic brand, launch and organization plans for pre-commercial rare disease companies.

Previously, until 2018, Mr. Smith was the Senior Vice President of Sales and Executive Leadership Team member at Actelion, where he spent more than eleven years in various senior commercial leadership roles. As the principal sales leader, Mr. Smith managed all U.S. sales operations, including sales, training, sales operations, patient & professional advocacy, key customer engagement and territory management.

Mr. Smith spearheaded two successful blockbuster PAH drug launches, OPSUMIT and UPTRAVI, which ultimately led to the purchase of Actelion by Johnson & Johnson in 2017 for $30 billion.

Before joining Actelion, Mr. Smith held various pharmaceutical marketing and sales leadership roles, with a focus on cardiovascular franchises, at Nuvelo, Johnson & Johnson, and Bristol-Myers Squibb. Mr. Smith received a B.B.A. in Marketing from Texas A&M University.

Mr. Waage is our Executive Vice President of Technical Operations & Administration. Previously, Mr. Waage held various positions from November 2013 to August 2016 at Receptos, Inc., most recently serving as Managing Director after its acquisition by Celgene Corporation, previously serving as Senior Vice President and General Counsel. From 2012 through its acquisition by Vista Equity Partners LLC in 2013, he served as Vice President, General Counsel and Corporate Secretary at Websense, Inc. From 2008 through its acquisition by AstraZeneca PLC in 2012, Mr. Waage served as Vice President, General Counsel and Corporate Secretary of Ardea Biosciences, Inc. Prior to 2008, Mr. Waage served as a partner at DLA Piper LLP. He has been a member of the board of directors of Heron Therapeutics, Inc. since June 2016. Mr. Waage received his J.D. from the University of San Diego, School of Law and a B.A. degree in economics from the University of California, San Diego.

Deanna Weber is Senior Vice President, Human Resources of Gossamer Bio. She has over 25 years of diverse Human Resources experience in Biotechnology and Fortune 500 companies. She recently served as Human Resources Director at Celgene Corporation. Before joining Celgene in 2016, Deanna served as Senior Director, Human Resources at Ambrx, Inc. from 2004-2016 transitioning the company from start up through acquisition. She entered the biotechnology industry in 1998 at Collateral Therapeutics. Prior to joining the biotech industry, she served at Fidelity Investments and Pacific Gas & Electric. Deanna received her B.S. from California Polytechnic State University, San Luis Obispo and her MBA in Organizational Development from Westminster College.